Revalesio, a US-based clinical-stage pharmaceutical company, announced on Wednesday that it has revealed topline data from the completed Phase two RESCUE clinical trial of RNS60 (NCT04693715) in acute ischemic stroke (AIS) patients during an oral presentation at the Late-Breaking Science session of the International Stroke Conference (ISC) 2024.
RNS60, Revalesio's lead product candidate, consists of a stable formulation of saline saturated with oxygen through a proprietary process. The company says that RNS60 initiates a cascade of biological effects that show significant benefits in preclinical models of acute and chronic neurological disorders, while showcasing a strong safety profile in the 400+ patients who have been administered RNS60 in previous trials.
The company assessed the safety and signs of efficacy of RNS60 in RESCUE, a double-blinded, placebo-controlled, randomised proof-of-concept trial. The trial had two primary endpoints: safety and mortality. The product met its primary endpoints of safety and mortality, with similar rates of SAEs and numerically lower rates of mortality. Its high dose decreased infarct growth by 50% (nominal p
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study